[go: up one dir, main page]

SG48855A1 - 4,1-benzoxazepin derivatives and their use - Google Patents

4,1-benzoxazepin derivatives and their use

Info

Publication number
SG48855A1
SG48855A1 SG1996003103A SG1996003103A SG48855A1 SG 48855 A1 SG48855 A1 SG 48855A1 SG 1996003103 A SG1996003103 A SG 1996003103A SG 1996003103 A SG1996003103 A SG 1996003103A SG 48855 A1 SG48855 A1 SG 48855A1
Authority
SG
Singapore
Prior art keywords
group
optionally substituted
stands
hydrogen atom
optionally
Prior art date
Application number
SG1996003103A
Other languages
English (en)
Inventor
Hidefumi Yukimasa
Kazuaki Kitano
Masakuni Kori
Ryuichi Tozawa
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of SG48855A1 publication Critical patent/SG48855A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG1996003103A 1992-04-20 1993-04-17 4,1-benzoxazepin derivatives and their use SG48855A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9954192 1992-04-20
JP33994792 1992-12-21

Publications (1)

Publication Number Publication Date
SG48855A1 true SG48855A1 (en) 1998-05-18

Family

ID=26440672

Family Applications (2)

Application Number Title Priority Date Filing Date
SG1996003103A SG48855A1 (en) 1992-04-20 1993-04-17 4,1-benzoxazepin derivatives and their use
SG9903981A SG82630A1 (en) 1992-04-20 1993-04-17 4,1-benzoxazepin derivatives and their use

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG9903981A SG82630A1 (en) 1992-04-20 1993-04-17 4,1-benzoxazepin derivatives and their use

Country Status (13)

Country Link
EP (1) EP0567026B1 (fi)
KR (1) KR100293338B1 (fi)
CN (1) CN1044237C (fi)
AT (1) ATE235474T1 (fi)
AU (1) AU659543B2 (fi)
CA (1) CA2094335C (fi)
DE (1) DE69332792T2 (fi)
FI (1) FI119022B (fi)
HU (1) HUT71482A (fi)
NO (1) NO304520B1 (fi)
NZ (1) NZ247429A (fi)
RU (1) RU2145603C1 (fi)
SG (2) SG48855A1 (fi)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726306A (en) * 1992-04-20 1998-03-10 Takeda Chemical Industries, Ltd. 4,1-benzoxazepin derivatives and their use
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
AU1589895A (en) * 1994-02-09 1995-08-29 Takeda Chemical Industries Ltd. Optically active 4,1-benzoxazepine derivatives useful as squalene synthase inhibitors
DK0751774T3 (da) * 1994-03-24 2003-12-08 Merrell Pharma Inc Hypocholesterolæmiske mercaptoacetylamiddisulfid-derivater
TW401301B (en) * 1994-10-07 2000-08-11 Takeda Chemical Industries Ltd Antihypertriglyceridemic composition
CA2161849A1 (en) * 1994-11-01 1996-05-02 Kazuo Nakahama Production of optically active compounds
BR9505995A (pt) * 1994-12-23 1997-12-23 Pfizer Composto método para tratamentos e composição farmacêutica
CA2231052C (en) * 1995-09-13 2007-11-13 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
AU6944296A (en) * 1995-09-13 1997-04-01 Takeda Chemical Industries Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
US6537987B1 (en) * 1996-06-20 2003-03-25 Pfizer Inc. 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
AU6854598A (en) 1997-04-21 1998-11-13 Takeda Chemical Industries Ltd. 4,1-benzoxazepines, their analogues, and their use as somatostatin agonists
JP2001514256A (ja) 1997-09-02 2001-09-11 デュポン ファーマシューティカルズ カンパニー Ｈｉｖ逆転写酵素阻害剤として有用な５，５−ジ置換−１，５−ジヒドロ−４，１−ベンゾオキサゼピン−２（３ｈ）−オン類
US6063921A (en) * 1997-11-20 2000-05-16 Pharm-Eco Laboratories, Inc. Synthesis of 11-aryl-5,6-dihydro-11H-dibenz[b,e]azepines
US6207664B1 (en) 1998-11-25 2001-03-27 Pfizer Inc. Squalene synthetase inhibitor agents
WO2001098282A1 (en) * 2000-06-23 2001-12-27 Takeda Chemical Industries, Ltd Benzoxazepinones and their use as squalene synthase inhibitors
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
JO2409B1 (en) 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Second-phenyl carboxy amides are useful as lipid-lowering agents
JO2390B1 (en) 2001-04-06 2007-06-17 شركة جانسين فارماسوتيكا ان. في Diphenylcarboxamides act as lipid-lowering agents
US20040204500A1 (en) * 2001-06-28 2004-10-14 Yasuo Sugiyama Preventives/remedies for organ functional disorders and organ dysfunction
GB0125532D0 (en) * 2001-10-24 2001-12-12 Burton Michael Enzyme activity indicators
UA79300C2 (en) 2002-08-12 2007-06-11 Janssen Pharmaceutica Nv N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion
WO2004067008A1 (ja) 2003-01-28 2004-08-12 Takeda Pharmaceutical Company Limited 受容体作動薬
US7829552B2 (en) 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
US7323455B2 (en) 2004-03-24 2008-01-29 Wyeth 7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators
CA2625416A1 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
CN103965185B (zh) * 2014-03-28 2016-06-29 河北师范大学 含有噻唑基和酯基的1,5-苯并二氮杂卓化合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5735596A (en) * 1980-08-13 1982-02-26 Funai Corp Ester derivative of deoxyfluorouridine
US4374842A (en) * 1980-04-18 1983-02-22 Shionogi & Co., Ltd. 4,1-Benzoxazepines and compositions
JPS5735576A (en) * 1980-07-18 1982-02-26 Takeda Chem Ind Ltd 4,1-benzoxazepin-3-acetic derivative and its production
US4590187A (en) * 1983-11-17 1986-05-20 The Upjohn Company Phospholipase A2 inhibition using 4,1-benzoxazepine-2-(3H)-ones
DE3471101D1 (en) * 1983-11-17 1988-06-16 Upjohn Co N-substituted-5-phenyl-4,1-benzoxazepin-2(3h)-ones having therapeutic utility
US4758559A (en) * 1986-01-21 1988-07-19 Ciba-Geigy Corporation Pyrrolo[1,2-a] [4,1]benzoxazepine derivatives useful as calmodulin and histamine inhibitors
NZ239663A (en) * 1990-09-13 1993-07-27 Merck & Co Inc Ester derivatives of dioxabicyclo(3,2,1)-octane, medicaments, and a fungus which makes them
CA2105655A1 (en) * 1991-03-08 1992-09-09 Kent Neuenschwander Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors

Also Published As

Publication number Publication date
KR940005597A (ko) 1994-03-21
DE69332792T2 (de) 2004-01-15
CA2094335C (en) 2005-07-12
KR100293338B1 (ko) 2001-11-22
EP0567026A1 (en) 1993-10-27
DE69332792D1 (de) 2003-04-30
NO304520B1 (no) 1999-01-04
FI931763A (fi) 1993-10-21
EP0567026B1 (en) 2003-03-26
AU659543B2 (en) 1995-05-18
NZ247429A (en) 1995-06-27
FI931763A0 (fi) 1993-04-19
CA2094335A1 (en) 1993-10-21
RU2145603C1 (ru) 2000-02-20
FI119022B (fi) 2008-06-30
NO931433D0 (no) 1993-04-19
NO931433L (no) 1993-10-21
CN1044237C (zh) 1999-07-21
HUT71482A (en) 1995-11-28
CN1083481A (zh) 1994-03-09
HU9301164D0 (en) 1993-07-28
AU3700393A (en) 1993-10-21
SG82630A1 (en) 2001-08-21
ATE235474T1 (de) 2003-04-15

Similar Documents

Publication Publication Date Title
SG82630A1 (en) 4,1-benzoxazepin derivatives and their use
MY118904A (en) 4-oxo-1, 4-dihydro-3-quinolinecarboxamides as antiviral agents
RU93005332A (ru) Производные 4,1-бензоксазепина, фармацевтическая композиция, способ лечения
AU1163492A (en) 3-benzylidene-1-carbamoyl-2-pyrrolidone analog
ES8303411A1 (es) Un procedimiento para la preparacion de derivados de tiofilina o teobromina.
HK1036802A1 (en) Aminotetrazole derivatives useful as nitric oxide synthase inhibitors
EP1008592A3 (en) Cyclic amide derivatives which inhibit cathepsin K
EP1184373A4 (en) TRICYCLIC CONNECTIONS
IL108258A0 (en) Piperazine derivates, their preparation and pharmaceutical compositions containing them
TW427993B (en) New cephem compounds
BG105123A (en) Tetrahydroquinaline derivatives as glycine antagonists
EP0469156A4 (en) Glutathione derivative
WO1998053790A3 (en) Compounds that inhibit the binding of vascular endothelial growth factor to its receptors
MX9505054A (es) Derivados de ester de bisfenol.
MY109714A (en) Process for preparing 8-chloroquinolone derivatives
AU3648093A (en) Pyrrolidine derivatives useful as 5-HT3-antagonists
NZ505110A (en) Neuroprotective agents
AU1120688A (en) - 8-heterocyclo-ergoline derivatives useful in the treatment of extrapyramidal syndromes
AU8041394A (en) Pyridazinone derivatives, processes for production thereof
TW333554B (en) Benzidine derivative and electrophotosensitive material using the same
TW326439B (en) Octahydornaphthalene oxime derivatives for cholesterol biosynthesis inhibition, their preparation and use
CA2359031A1 (en) Thiazolidinone or oxazolidinone derivatives for treatment of ulcerative disease